No Data
Are Investors Undervaluing Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) By 42%?
China Approves Registration for King-Friend Biochemical Pharma Unit's Breast Cancer Injection
Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Shareholders Are up 13% This Past Week, but Still in the Red Over the Last Three Years
Announcement of the 2024 annual results forecast of Jianyou Co., Ltd.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Methylene Blue Injection has obtained the pharmaceutical registration approval from the USA FDA.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that the company recently received notice from the USA Food and Drug Administration (abbreviated as...
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): The expected net income for the year 2024 is between 0.8 billion yuan and 1.05 billion yuan.
Gelonghui, January 24: Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced the performance forecast for 2024. According to preliminary calculations by the finance department, it is expected that in 2024 the net income attributable to shareholders of the parent company will be between 800 million yuan and 1,050 million yuan, which represents a turnaround from a loss to a profit compared to the same period last year. It is also expected that the net income attributable to shareholders of the parent company, after deducting non-recurring gains and losses, will be between 750 million yuan and 1,000 million yuan.
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
